Swiss Biotech Association’s Post

Should biotech companies consider pricing implications for Early Access Programs? In this snippet from our recent webinar with Fierce Biotech, Andrew Cummins (VP of Business Development) gives his expert thoughts and advice. Download valuable insights from our latest webinar! Visit: https://lnkd.in/eP4C3bFU #ExpandedAccessPrograms #RareDiseases #OrphanDrugs #RealWorldEvidence #MarketAccess #biotechs Mathieu Loiseau Sara Radenovic

The overall picture of the Swiss biotech industry is quite positive. The Swiss Biotech Report recently published provides an analysis of the 2023 biotech funding as well as other key ratios and statistics: https://lnkd.in/dGSvh2d With Swiss Biotech Association https://lnkd.in/dAtS7hyU

Watch now: Prescient Therapeutics’ CEO & MD Steven Yatomi-Clarke provides an update on our strategy and upcoming milestones 💡 https://hubs.ly/Q02qRymS0 Focusing on PTX-100, Steven discusses how the upcoming PTX-100 Phase 2 trials places the company at a major value inflection point. #Biotech #PTX100 #CellTherapies #CancerTherapies

Listen to my colleague Michael J. Tarlov describe the development of the National Institute of Standards and Technology (NIST) Biomanufacturing Program, which provides the #biopharmaceutical and #biotech sectors with measurements and reference materials for their processes and product quality assurance. https://lnkd.in/eV--AAij

Q3 Biotech Roundup: The 2024 Turnaround Faces a Pivotal Q4 As we approach a crucial Q4, several key indicators of biotech activity are showing tentative signs of improvement. While the recovery is not yet widespread, there are indications that the industry may be inching closer to a return to robust growth.

🔬✨ Could Soligenix (SNGX) be the next big winner in biotech? 🤔 In our latest video, we dive deep into their groundbreaking HyBryte study and explore the future potential of this innovative biopharma company. 🚀💡 Discover Soligenix's recent achievements, upcoming milestones, and why HyBryte stands out as a promising treatment in the biotech landscape. 🌟🔍 Join us as we analyze the key factors that could drive Soligenix's growth and find out if SNGX stock is a smart investment for the future. 📈💰 Watch now to get the inside scoop! 🎥 https://lnkd.in/dHArNM8R

The date is approaching! 📆 In a few days the Syngoi Technologies team will be in #Frankfurt at the 2nd edition of the mRNA Process Development and Manufacturing Conference. Julen Oyarzabal will give a session on the implementation of #innovations to improve the starting material. As well as on improved and advanced #mRNA manufacturing. We look forward to seeing you! #celltherapy #biotech #manufacturingmRNA #chemicalbiology

Today's the day. Check out my presentation at Fierce Biotech JPM week on success factors for the biotech company journey from discovery to commercialization. You can register here. https://lnkd.in/eQTYR4nE

SFBN Feed: It takes GUTS to be BOLD: A look at the new biotech tickers https://lnkd.in/gAijC39m As the public markets heat up in biotech, industry insiders expect a small drumbeat of IPOs later this spring, and that means a new set of stock tickers to track. Next up is BOLD, the [...] #BayArea #SanFrancisco #Biotech #Lifescience #News

Recently found this interesting article that dives into the ongoing debate between product and platform approaches in the biotech world - highly recommended for industry enthusiasts! 🧬 Link to the article here 👉🏼  https://lnkd.in/d7UcVYxh